D-dimer before chemotherapy might predict venous thromboembolism
D-dimer before chemotherapy might predict venous thromboembolism
复制标题
DOI：
10.1097/mbc.0b013e32831bc2de
复制
发表时间：
2009-04-01
影响因子：
1.1
通讯作者：
Cimminiello, Claudio
中科院分区：
文献类型：
--
作者：
Arpaia, Guido;Carpenedo, Monica;Cimminiello, Claudio
以了解D-二聚体水平是否可以识别静脉血栓事件的高危患者，并建立最佳的益处/出血风险比。目前的指南不建议对接受化疗的癌症患者进行常规预防静脉血栓栓塞症(VTE)，但由于这种治疗，风险增加了约6.5倍。对124名计划进行首次化疗的癌症患者进行了基线D-二聚体检测。在治疗的前6个月记录VTE事件，包括有症状的深静脉血栓形成和/或肺血栓形成，并在基线、90天和180天后通过压力超声显示无症状的深静脉血栓形成。随访期间共发生VTE 11次(8.9%)。静脉血栓栓塞组D-二聚体均值(2195+/-1382 ng/ml)高于对照组(695+/-1039 ng/ml)(P
To see whether D-Dimer levels can identifying patients at high risk of venous thrombotic events and establish the best benefit/risk-of-bleeding ratio. Current guidelines do not recommend routine prophylaxis against venous thromboembolism (VTE) in cancer patients receiving chemotherapy, but the risk increases about 6.5-fold because of this treatment D-dimer was measured at baseline in 124 cancer patients scheduled for their first chemotherapy. VTE events, including symptomatic episodes of deep vein thrombosis or pulmonary embolism or both, were recorded during the first 6 months of therapy, and asymptomatic deep vein thrombosis was revealed by compression ultrasonography at baseline and after 90 and 180 days. During follow-up, there were 11 episodes of VTE (8.9%). Mean D-dimer values were higher in patients with VTE (2195 +/- 1382 vs. 695 +/- 1039 ng/ml, (P